類風濕性關節炎 / Rheumatoid Arthritis (RA)

如你有此疾病,請遵照閣下醫生的完整醫療方案;而是否使用多學科復康方案前,你必須咨詢主診醫生的意見,如果閣下的主診醫生不建議您加入補充劑調理組合,請你不要使用。如果你需要尋求其他醫生作第二咨詢,閣下可聯絡我們線上<無邊界醫生>。或你自己城市內的其他專業醫生的再診斷。

類風濕性關節炎 / Rheumatoid arthritis (RA)

類風濕性關節炎(RA)是一種慢性全身性自身免疫性疾病,主要影響滑膜關節襯裡,與進行性殘疾、過早死亡和社會經濟負擔有關。迫切需要更好地理解病理機制是如何導致個體RA進展惡化的,以便開發出在疾病進展的每個階段有效治療患者的療法。在這裡,我們解剖了特定階段的病因和病理:(i)觸發,(ii)成熟,(iii)靶向,和(iv)暴發性階段,伴隨著滑膜增生,軟骨損傷,骨侵蝕和全身後果。現代藥物治療(包括傳統的、生物的和新的潜在的小分子疾病修飾的抗風濕藥物)仍然是RA治療的主流,並且在實現疾病緩解而無關節畸形方面取得了重大進展。儘管如此,相當一部分類風濕關節炎患者對現時的治療沒有有效的反應,因此迫切需要新的藥物。

If you have this disease, please follow your doctor's complete medical plan. You must consult the attending doctor before using the multidisciplinary rehabilitation plan. If your attending doctor does not recommend you to join the supplement conditioning combination, please do not use it. If you need to seek second consultation from other doctors, you can contact our online "Doctors Without Borders", or another professional doctor in your own city.

Rheumatoid arthritis (RA)

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects the lining of the synovial joints and is associated with progressive disability, premature death, and socioeconomic burdens. A better understanding of how the pathological mechanisms drive the deterioration of RA progress in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of the disease progress. Here we dissect the etiology and pathology at specific stages: (i) triggering, (ii) maturation, (iii) targeting, and (iv) fulminant stage, concomitant with hyperplastic synovium, cartilage damage, bone erosion, and systemic consequences. Modern pharmacologic therapies (including conventional, biological, and novel potential small molecule disease-modifying anti-rheumatic drugs) remain the mainstay of RA treatment and there has been significant progress toward achieving disease remission without joint deformity. Despite this, a significant proportion of RA patients do not effectively respond to the current therapies and thus new drugs are urgently required.

Refs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59200...